Skip to content

ASPIRE 2: Action to Support Practices Implementing Research Evidence

A cluster-randomised evaluation of adaptable implementation packages targeting high impact clinical practice recommendations in general practice

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN91989345
Enrollment
144
Registered
2015-02-20
Start date
2015-02-27
Completion date
Unknown
Last updated
2023-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Diabetes, Primary Care

Interventions

1. Audit and Feedback: This will be by practice and will be repeated regularly during the trial. It will include comparisons with other (anonymised) practices, information to illustrate benefits of ch

Sponsors

University of Leeds
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: General practices within the ten Clinical Commissioning Groups (CCGs) in West Yorkshire (Airedale Wharfedale and Craven CCG, Bradford City CCG, Bradford Districts CCG, Calderdale CCG, Greater Huddersfield CCG, Leeds North CCG, Leeds South and East CCG, Leeds West CCG, North Kirklees CCG, Wakefield CCG) will be eligible to participate in the trial provided they use the IT System, SystmOne clinical software for patient health records.

Exclusion criteria

Exclusion criteria: 1. We will exclude the four general practices which participated in earlier pilot intervention work as they will already have been exposed to active intervention components. We will also exclude general practices where we have already interviewed GPs, nurses and practice managers as part of the intervention development process and which participate in the planned qualitative process evaluation (which will be the subject of a further protocol and ethics application). 2. Any general practices that do not use SystmOne software for patient health records will also be excluded.

Design outcomes

Primary

MeasureTime frame
Adherence; Timepoint(s): Adherence will be measures up to 12 mth post randomisaion

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 3, 2026